摘要
目的:探讨利拉鲁肽对肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者的疗效以及对心外膜脂肪组织(epicardial adipose tissue,EAT)厚度的影响。方法:选取本院2016年6月-2017年6月收治的T2DM患者92例,按照随机数字表法将其分为观察组和对照组,各46例。对照组给予盐酸二甲双胍治疗,观察组在对照组基础上给予利拉鲁肽皮下注射治疗,均治疗12周。比较两组治疗前后的体重指数(BMI)、腰围指标、空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、甘油三酯和EAT水平,记录治疗过程中的不良反应。结果:治疗后,两组BMI、腰围指标、FPG、2 h PBG、HbA1c和甘油三酯水平均低于治疗前,且观察组均低于对照组,比较差异均有统计学意义(P<0.05);治疗后,观察组EAT厚度低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:利拉鲁肽治疗T2DM可有效改善糖尿病的常规监测指标,且对EAT厚度有一定的改善作用,值得推广应用。
Objective：To investigate the effect of Liraglutide on the efficacy of obese patients with type 2 diabetes mellitus（T2DM） and the thickness of epicardial adipose tissue（EAT）.Method：A total of 92 patients with T2DM from June 2016 to June 2017 in our hospital were selected.According to the random number table method,they were divided into observation group and control group,46 cases in each group.The control group was treated with Metformin Hydrochloride,and observation group was treated with Liraglutide subcutaneous injection on the basis of control group,all patients treated for 12 weeks.The body mass index（BMI）,waist circumference,fasting blood glucose（FPG）,postprandial blood glucose（ 2 h PBG）,glycosylated hemoglobin （HbA1c）,triglyceride and EAT before and after treatment between two groups were compared,and the adverse reactions during treatment were recorded.Result：After treatment,BMI,waist circumference,FPG,2 h PBG, HbA1c,triglyceride in two groups were lower than those of before treatment,and the observation group were lower than those of control group,the differences were statistically significant（P〈0.05）.After treatment,the thickness of EAT in observation group was lower than that of control group（P〈0.05）.The incidence of adverse reactions in two groups were compared,the difference was not statistically significant（P〉0.05）.Conclusion：Liraglutide treatment of T2DM can effectively improve the routine monitoring indicators of diabetes mellitus,and the thickness of EAT has a certain improvement effect,it is worthy of promotion and application.
作者
林华容
余锡河
张群
蔡毅峰
LIN Huarong;YU Xihe;ZHANG Qun(Chaozhou Central Hospital,Chaozhou 521000,China)
出处
《中国医学创新》
CAS
2018年第27期34-37,共4页
Medical Innovation of China
基金
潮州市科技计划项目(2015GY25)
